FDA appropriations
Executive Summary
FDA is funded at $1.22 bil. in fiscal 2001, $34.7 mil. above the FY 2000 level and $89 mil. below the President's request in the Agriculture Appropriations conference report passed by the Senate Oct. 18. CDER is funded at $317.5 mil. and CBER at $140.5 mil. The conferees approved funding increases of $22.9 mil. for premarket review, $9 mil. for inspections, $5 mil. for enforcement of Internet drug sales and $6.8 mil. for post-approval surveillance. The report includes $23 mil. for FDA to implement regulations allowing the reimportation of Rx drugs "upon submission of an official budget request." The conference report passed the House Oct. 11 and President Clinton is expected to sign it into law
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth